The Impact of Ulipristal Acetate (UPA) versus Dienogest on Pain Related to Endometriomas Evaluated with Visual Analogue Scale (VAS)

ROMINA MARINA SIMA, DRAGOS ALBU, ANTONIU CRINGU IONESCU, MIHAI DIMITRIU, MIHAI POPESCU, DANA-RODICA TOMESCU, RADU CHICEA, IULIANA CEASUS, IOAN-ILIAN IORDACHE, MIRCEA-OCTAVIAN POENARU, ALEXANDRA MATEI, ALINA CALIN, LIANA PLES

1 Carol Davila University of Medicine and Pharmacy, Department Obstetrics Gynecology, Bucharest, Romania
2 Carol Davila University of Medicine and Pharmacy, Maternal-Foetal and Reproductive Medicine Department, Medlife, Bucharest, Romania
3 Carol Davila University of Medicine and Pharmacy, Department Obstetrics Gynecology, Bucur Maternity, St. John Hospital, Bucharest, Romania
4 Carol Davila, University of Medicine and Pharmacy, Department of Anesthesiology and Critical Care III, Fundeni Clinical Institute, Bucharest, Romania
5 University of Medicine and Pharmacy Lucian Blaga, Faculty of Medicine, 10 Victoriei Blvd., 550024, Sibiu, Romania
6 Carol Davila University of Medicine and Pharmacy, Department Obstetrics Gynecology, Dr. I. Cantacuzino Hospital, Bucharest, Romania
7 Department of Gynecology and Obstetrics, Saarland University Hospital, Kirrbergerstraße 100, 66421, Homburg, Germany
8 Dunarea de Jos University of Galati, 47 Domneasca Str, 800008, Galati, Romania

Visual analogue scale (VAS) is a psychometric scale applied to measure subjective characteristics. The purpose of our study was to evaluate the efficiency of Ulipristal acetate (UPA) compared with Dienogest for endometriomas related pain using VAS. We performed a randomized study on women with symptomatic endometriomas. The study was realized between January 2016–December 2018. The patients were randomized in two groups: Group A - that received UPA in doses of 5 mg daily for 12–13 weeks and Group B that received 2 mg Dienogest for 12–13 weeks. Each group received de VAS (Visual Analogue Scale) questionnaire before and after treatment. 70 women were included in the study with 35 patients for each group. The age the mean age was 30.20 years. For Numeric Rating Scale before treatment in the group with UPA median value was 6 (CI= 5.26, 6.51) and for group B the median was 5 (CI= 5.13, 5.66). After treatment for group A the median value was 4 (CI= 3.58, 4.29) and for group B the median value 4 (CI= 5.13, 5.66). For FRS before treatment in the group with UPA median value was 6 (CI= 5.87, 6.58) and for the group B median was 6 (CI= 6.16, 6.57). After treatment for group A the median value was 4 (CI= 4.12, 4.73) and for group B the median value 5 (CI= 4.9, 5.06). The pain significantly improved for group A. (p< 0.05)

Keywords: endometriosis, VAS, dienogest, ulipristal, pain

Endometriosis is represented by ectopic implants of endometrial cells that cause local inflammatory response[1]. The pathogenesis is controversial but it includes altered immunity, aberrant endocrine signalling or genetic factors with six genomic regions affected[2]. Endometriosis treatment is medical or surgical. The medical classes used for endometriosis treatment are: nonsteroidal analgesics, gonadotropin-releasing hormone (GnRH), agonists hormonal contraceptives and aromatase inhibitors. There is a lack of data to prove that one treatment or combination is better than another. The treatment is guided by symptom severity, treatment efficacy, medication side effects, contraceptive needs, costs, patient preferences and availability[3].

It was observed that for women with pelvic pain caused by endometriosis or for the ones who have contraindications for combined estrogen-progesterin contraceptives, progesterin-only represents a good treatment option. The most used progestins administered for the treatment of endometriosis-related pain are medroxyprogesterone acetate and Dienogest[4]. In recent systematic reviews about progestin therapy for endometriosis Dienogest was superior to placebo[5].

Progesterone receptors antagonists were used in the early 1990 by Philibert et al as contraceptive drugs and nowadays there is produced a wide spectrum of similar drugs with PR (progesterone receptor) agonist and antagonist effects[6]. Ulipristal acetate (UPA) is introduced and approved since 2009 for leiomyomas treatment and contraceptive reasons by the EMA (European Medicines Agency) and in 2010 by FDA (U.S. Food and Drug Administration). UPA is a dose dependent PR antagonist and agonist with impact on endometrium and myometrium. It acts as PR antagonist with contraceptive effect, also in unique administration (emergency contraception)[7]. Lately the therapeutic indication of UPA were extended to endometriosis as well.

The therapeutic response for endometriosis use is related to symptoms reduction and quality of life improvement. For quality of life and evaluation there are many standard questionnaires. Among those visual
analogue scales (VAS) are psychometric scales applied to measure subjective characteristics. At the beginning they were used for different types of disorders, and for research and social investigations purpose[8]. We performed a randomized study about the efficiency of UPA compared with dienogest for endometriomas related pain using VAS.

Experimental part

A randomized study was conducted on women with symptomatic endometriomas. The study is multicentre centre study, extended between January 2016–December 2018. Ethical approval and patient’s informed consent for treatment and study were obtained.

The study included women with symptomatic endometriomas that received conservative management. Transvaginal ultrasound was performed by two experienced sonographists and the endometriomas were measured and mapped. It was considered only the largest diameter of the endometrioma and in order to reduce biasses the same doctor evaluated the same patient at the beginning and at the end of the treatment.

The inclusion criteria were: women with symptomatic endometriomas, that involved one or both ovaries, the endometriomas dimension under 5 cm and patients that agreed with the study. Exclusion criteria were: patients who didn’t accept the study, other types of endometriosis such as deep infiltrative endometriosis, endometriomas with diameters over 5 cm that had indication for surgical approach.

A randomized controlled study was designed. The patients were randomized from the beginning in two groups: Group A- that received UPA in doses of 5 mg daily starting with the first or second menstrual day for 12-13 weeks and Group B that received 2 mg Dienogest starting with the first or second menstrual day for 12-13 weeks. Each group received de VAS (Visual Analogue Scale) questionnaire before and after treatment.

The randomization was made according to seal envelope method. The patient signed the inform and then the patient selected a sealed envelope from a pile opened it in front of the person that was in charge for recruiting patients for the trial. Then the patient was distributed in one of the categories. The physicianshow performed the ultrasound scan were blinded. Patients were informed about their treatment and signed the informed consent. The statistician was informed that there were 2 groups: A and B. He did not have any information regarding the patient treatment. At the end of the treatment courses the patients were examined by ultrasound and filled VAS questionnaire.

Statistical analysis was carried out with Statistical Package for Social Sciences (SPSS) Software 25.0. The differences between the treatment groups were evaluated by One Way ANOVA and t-test. Data were expressed as mean ± standard deviation (std dev). Pearson’s correlation was used as appropriate and two-sided p-values of <0.05 were considered to indicate statistical significance.

Results and discussions

A group of 70 women was randomized in our study with 35 patients for each group. The main group characteristics for the entire study group are illustrated in Table 1. The age of the patients included in the study group varied between 18 and 42 years, the mean age being 30.20 years. Clinical symptoms severity, timing and all other significant information related to endometriosis were obtained. History of each patient was obtained and it revealed that 54.3% of the patients from the whole study group had previous surgical interventions for endometriosis. The main complains were dyspareunia, dysmenorrhea as reported in Table 1. Overall the patients described an altered quality of life due to endometriosis symptoms but it improved in 74.3 % cases after treatment. For UPA group 80% patients admitted that quality of life improved whereas 68.6% patients from Dienogest group described such association.

All the patients underwent ultrasound examination. Regarding endometriomas distribution it was observed that 37.1 % involved the right ovary, 42.9 % affected the left ovary and 20% were bilateral. It was identified that before treatment the mean endometrioma dimension was 3.63 cm and decreased to the mean dimension of 3.49 cm (p<0.001) for the entire study groups. Endometriomas dimensions diminution after UPA and Dienogest treatment (p<0.001) is detailed in table 2.

### Table 1

| The Study Group Characteristics |
|-------------------------------|
| **Age (years)** | 30.20 years (mean) | (min: 18 years, max: 42 years, std dev: 5.78) |
| **Endometriomas dimension before treatment [mm]** | 3.62 cm (mean) | (min: 2 cm, max: 4.7 cm, std dev: 0.66) |
| **Endometriomas dimension after treatment [mm]** | 3.49 cm (mean) | (min: 1.8 cm, max: 4.5 cm, std dev: 0.57) |
| **Dyspareunia** | Yes 72.5% | No 27.1% |
| **Dysmenorrhea** | Yes 71.4% | No 28.6% |
| **Previous operations** | Yes 54.3% | No 45.7% |
| **Quality of life improvement** | Yes 74.3% | No 25.7% |
The main purpose of the present study was to characterize the pain associated to endometriomas. To the first point of the scale (Option 1) with 10 points for no pain and 0 points for worst pain ever it is observed from images 1 (a and b) the characteristics of pain before and after treatment. Before treatment in the group with UPA the median value was 4 (CI= 3.75, 4.64) and for the group B the median was 5 (CI= 4.22, 4.97). After treatment for group A the median value was 6 (CI= 5.33, 6.28) and for group B the median value 6 (CI= 5.38, 5.93). The pain significantly improved for group A (p< 0.001) (fig. 1 a, b).

For the second point of the scale (Option 2) with 10 points for worst pain ever and 0 points for no pain it is observed from images 2 (a and b) the characteristics of pain before and after treatment. Before treatment in the group with UPA the median value was 6 (CI= 5.29, 6.18) and for group B the median was 6 (CI= 5.11, 5.85). After treatment for group A the median value was 4 (CI= 3.6, 4.39) and for group B the median value 5 (CI= 4.26, 4.93). The pain significantly improved for group A (p< 0.001) (fig. 2 a, b).

For the third point of the scale (NRS-Numeric Rating Scale) with 10 points for worst possible pain and 0 points for no pain it is observed from images 3 (a and b) the characteristics of pain before and after treatment. Before treatment in the group with UPA the median value was 6 (CI= 5.26, 6.51) and for group B the median was 5 (CI= 5.13, 5.66). After treatment for group A the median value was 4 (CI= 3.58, 4.29) and for group B the median value 4 (CI= 4.23, 4.6). The pain significantly improved for group A (p< 0.001) (fig. 3 a,b).

For the fourth point of the scale (FRS-Face Rating Scale) with 10 points for hurts and 0 points for no hurt it is observed from images 4 (a and b) the characteristics of pain before and after treatment. Before treatment in the group with UPA the median value was 6 (CI= 5.87, 6.58) and for group B the median was 6 (CI= 5.16, 5.67). After treatment for group A the median value was 4 (CI= 4.12, 4.73) and for group B the median value 5 (CI= 4.9, 5.06). The pain significantly improved for group A (p< 0.001) (fig. 4 a,b).

Functional Activity Score (FAS) was also evaluated before and after treatment. It can be observed from Table 3 that there was significant improvement of activity because of endometriosis treatment. The group A had mild limitation of activity in 88.6% cases and 11.4% cases before UPA administration. For group B the limitation of activity was severe for 85.7% cases and mild for 14.3% cases and after Dienogest administration the limitation was severe for 84.9% cases and mild for 15.1% cases.
for 68.6% and remained severe for 31.4% cases. Overall
the treatment improved the activity for patients with
endometriosis but UPA was more efficient in this study
(table 3).

VAS was first introduced in 1921 and it was initiated as
a graphic rating method [9]. It is considered that the main
advantage of this method is that it offers the possibility to
evaluate detailed subtypes of judgement of the patient. It
also requires the patient hand-eye coordination and visual
ability[10]. The most important disadvantage is that it can
be used in written (or digital) format and not for oral
interviews and considerable effort for data entry and
statistical analysis [11].This is the first study that compare
the therapeutic effect of UPA and Dienogest in
endometriosis related symptoms evaluated using VAS. In
the present study we observed that overall both UPA and
Dienogest ameliorate the pain for patients with
endometriomas. There are significant changes regarding
dysmenorea (from 72.9 to 27.1%), dyspareunia (from
71.4 to 28.6%) and quality of life improvement dyspareunia
(from 74.3 to 25.7%). The parameters of VAS suffered
significant changes after treatment. It was identified that
UPA and Dienogest improved pain with impact on numeric
rating scale and face rating scale, but UPA results were
superior to Dienogest results. The pain significantly
improved for group A. (p< 0.05)

The purposes of endometriomas treatment are to
remove the symptoms as pain, to reduce the tumor
dimensions, to improve subfertility or to avoid and prevent
complications such as the cyst rupture or torsion. It was
observed that medical therapy did not resolve
endometriomas completely[12]. Symptomatic or rapidly
increasing endometriomas are treated laparoscopically. It
was proved that laparoscopy improves the quality of life
and sexual function after different procedures in pelvic area
such myomectomy[13] and for all types of endometriosis
with laparoscopic approach [14,15]. The most important
disadvantage of endometriomas surgical removal is that
the ovarian reserve diminish with each procedure. For
ovarian protection reserve, asymptomatic and small
ovarian endometriomas (< 5 cm) can benefit from medical
approach [16].

Estrogen expression suppression and progesterone
receptors activation represent the essential target for
current drugs, and also for research and new drugs
development. The most used and studied agents for

| group   | Frequency after | Percent after | Frequency before | Percent before |
|---------|-----------------|---------------|------------------|---------------|
| UPA     |                 |               |                  |               |
| Valid   | no limitation   | 1 2.9         | 0                | 0             |
|         | mild limitation | 25 71.4       | 31               | 11.4          |
|         | severe limitation | 9 25.7   | 35               | 88.6          |
|         | Total           | 35 100.0      | 5                | 100.0         |
| Dienogest|                |               |                  |               |
| Valid   | mild limitation | 24 66.6       | 4                | 14.3          |
|         | severe limitation | 11 31.4   | 31               | 85.7          |
|         | Total           | 35 100.0      | 100.0            | 100.0         |

Table 3
FAS SCORE BEFORE AND AFTER TREATMENT
endometriosis treatment are oral GnRH antagonists, aromatase inhibitors SERMs (Selective Estrogen Receptor Modulators) and SPRMs [17-19]. UPA is generally prescribed for conservative treatment of fibroids to preserve fertility. UPA was approved treatment for uterine fibroids since 2012. The action on the myometrium are antiproliferative, antifibrotic and proapoptotic with reduction a fibroid volume reduction up to 45%[20]. UPA effect is safe for endometrium[21].

The clinical effects of Dienogest for endometriosis treatment are reported in different studies and it was observed that it reduces the size of endometriomas and determine symptome relief for women with recurrent endometriosis [22]. Dienogest is efficient and safe for management of endometriosis associated pelvic pain[23] and avoid pain recurrence post surgery. Dienogest is well tolerated and side effects can be clinically managed [24]. Vaginal treatment with dienogest is innovative for symptomatic deeply infiltrating rectovaginal endometriosis and should receive further investigation in pharmacokinetic and clinical studies [25]. On the ovary, Duphaston and Dienogest are effective progestins that can be used as oral contraceptive with different ovulation inhibitory effects [26,27]. The ovulation inhibitory effect induced by Dienogest could be reverse rapidly by stopping treatment [28,29]. Studies demonstrated the beneficial effect on pain generated by cyst endometrioma [30]. Side effects of progesin are represented by irregular uterine amenorrhea (dienogest), mood changes (depression) weight gain, and bone loss[31].

UPA and Dienogest are proved to be effective as anti-endometriosis drugs inducing apoptosis and reducing proliferation and adhesions. UPA and Dienogest are very well tolerable by the patient. For Dienogest use endometrial glandular hyperplasia was described and follicle accumulation for UPA [32]. Ulipristal acetate can control irregular bleeding by inducing amenorrhea while Dienogest may cause irregular uterine bleeding [33,34].

This study is a pilot research that compares the effects of UPA versus Dienogest symptomatic patients with endometriomas evaluated by VAS. The strength of our study is represented by the accuracy of the protocol with good applicability before and after treatment. The limitation of the study is the reduced number of patients.

**Conclusions**

VAS represent a good method to evaluate the quality of pain for patients with endometriomas. The UPA and Dienogest treatment improve the VAS parameters with better results for UPA in the present study. Further research is needed aiming also other administration ways (vaginal) and on larger patients cohorts to assess the benefits and the safety of UPA in endometriosis.

Acknowledgement: This work was supported by University of Medicine and Pharmacy Carol Davila a project number 5782/08.03.2018

**References**

1. GIUDICE LC. Clinical practice. Endometriosis. N Engl J Med 2010; 362:2369.
2. RAHMIIOGLU N, NYHOLT DR, MORRIS AP, ET AL. Genetic variants underlying risk of endometriosis: insights from meta-analysis of eight genome-wide association and replication datasets. Hum Reprod Update 2014; 20:702.
3. DUNSELMAN GA, VERMEULEN N, BECKER C, et al. ESHRE guideline: management of women with endometriosis. Hum Reprod 2014; 29-400.
4. Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain associated with endometriosis: a committee opinion. Fertil Steril 2014; 101:927.
5. BROWN J, KIVES S, AKHTAR M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database Syst Rev 2012; CD002122.
6. PHILIBERT D, RU38486: An original multifaceted anti hormone in vivo. In Agarwal M (ed.) Adrenal Steroid Antagonism.Walter de Gruyter and Co, Berlin, 1984; 77-101.
7. CHABBERT-BUFFET N, MEDURI G, BOUCHARD P, SPITZ I. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Human Reproduction Update 2005; 11(3): 293-307.
8. FLYNNND, VANSCHAIPK, VANWERSCHKA.A comparison of multiitem likert and visual analogue scales for the assessment of transactionally defined coping. Eur J Psychol Assess. 2004;20:49-58.
9. HAYES MHS, PATERSON DG. Experimental development of the graphic rating method. Psychol Bull. 1921;18:98-9.
10. DUNCAN GH, BUSHNELL MC, LAVIGNE GJ. Comparison of verbal and visual analogue scales for measuring the intensity and unpleasantness of experimental pain. Pain. 1989;37:295-303.
11. KRAUTH J. Testkonstruktion und Testtheorie. Weinheim: BeltzPuV,1995.
12. CHAPRON C, VERCELLINI P, BARAKAT H, ET AL. Management of ovarian endometriomas. Hum Reprod Update 2002; 8:591.
13. RADOSA JC, RADOSA CG, MAVROGA R, WAGENPFEIL S, HAMZA A, JUKHADAR BA, BAUM S, KARSTEN M, JUHASZ BOESS I, SOLOMAYER EF, RADOSA MP. Postoperative Quality of Life and Sexual Function in Premenopausal Women Undergoing Laparoscopic Myomyectomy for Symptomatic Fibroids: A Prospective Observational Cohort Study. PLoS One. 2016 Nov 29;11(11):e0166559.
14. ARCOVERDE FVL, ANDRES MR, BORRELLI GM, BARBOSA PA, ABRAO MS, KHO RM. Surgery for Endometriosis Improves Major Domains of Quality of Life: A Systematic Review and Meta-Analysis. j Minim Invasive Gynecol. 2018 Sep 20. pii: S1553-4650(18)31244-5.
15. BADOIU DC, SIMA RM, MEHEDITNU C, MASTALIERB, MANDU M, ANDRONACHE LF, PADURARU DN, STOIAN AP, GRIGOREAN VT. Abdominal-pelvic pain in female patients with endometriosis - a review of the literature. J Mind Med Sci. 2018; 5(2): 158-162.
16. RAFFI F, METWALLY M, AMER S. The impact of excision of ovarian endometriomyoma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97:3146.
17. CLEMENZA S, SOBBI F, NOCI I, CAPEZZUOLI T, TURRINI I, CARRIERO C, BUFFI N, FAMBRSINI M, PETRAGLIA F. From pathogenesis to clinical practice: Emerging medical treatments for endometriosis. Best Pract Res Clin Obstet Gynaecol. 2018 Aug 51:92-101.
18. DUCCEO L, D., LUCA, A. C., MITREA, G., BANU, E.A., CIUHODARU, M.I., CIOMAGA, I., ICHIM, D.L., BACIU, G., Ceftriaxone Intercalated Nanostructures Used to Improve Medical Treatment. Mat. Plast., 2018, no.4, 2018, p.613-615.
19. LUCA, A. C., DUCCEO L. D., MITREA, G., CIUHODARU, M.I., ICHIM, D.L., BACIU, G., BANU, E.A., IORDACHE, A.C., Antibiotic Encapsulated Nanomaterials with Application in Medical Area. Mat. Plast., 55, no.4, 2018, p.552-554.
20. DONNEZ J, TATARCHUK TF, BOUCHARD P, PUSCASLIU L, ZAKHARENKO NF, IVANOVA T, IVANOVA T, UGOCSAI G, MARA M, JILLA MR, BESTEL E, TERRILL P, OSTERLOH I, LOUMAYE E, PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med, 2012, 366(5):409-420.
21. PLES L, SIMA RM, CARP D, FLORESCU C, DIMITRIU MCT, IONESCU CA. UPA effects on endometrium - what is the significance? Rom J Morphol Embryol. 2018;59(4):1127-1132.
22. LEE JH, SONG YJ, YI KW, LEE SR, LEE DY, SHIN JH, CHO S, SEO SK, KIM SH. Effectiveness of Dienogest for Treatment of Recurrent Endometriosis: Multicenter Data. Reprod Sci. 2018 Oct;25(10):1515-1522.
23. YU Q, ZHANG S, LI H, WANG P, ZVOLANEK M, REN X, DONG L, LANG J. Dienogest for Treatment of Endometriosis in Women: A 28-Week, Open-Label, Extension Study. J Womens Health (Larchmt). 2019 Feb;28(2):170-177.

24. ROMER T. Long-term treatment of endometriosis with dienogest: retrospective analysis of efficacy and safety in clinical practice. Arch Gynecol Obstet. 2018 Oct;298(4):747-753.

25. EBERT AD. Daily Vaginal Application of Dienogest (Visanne©) for 3 Months in Symptomatic Deeply Infiltrating Rectovaginal Endometriosis: A Possible New Treatment Approach? Case Rep Obstet Gynecol. 2018 May 10;2018:8175870.

26. ENDRIKAT J, PARKE S, TRUMMER D, SERRANI M, DUIJJKERS I, KLIPPING C. Pituitary, ovarian and additional contraceptive effects of an estradiol-based combined oral contraceptive: results of a randomized, open-label study. Contraception. 2013;87:227-34.

27. IONESCU C.A, NAVOLAN D, CALIN A, MATEI A, BOHILTEA R, DIMITRIU M, ILINCA C, PLES L. Hormonal Contraception in Postpartum Patients with Gestational Diabetes Mellitus. Rev.Chim.(Bucharest), 69, no 2, 2018, p.478-483.

28. KLIPPING C, DUIJKERS I, REMMERS A, FAUSTMANN T, ZURTH C, KLEIN S, SCHUETT B. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52:1704-13.

29. PACU I, IONESCU C.A, VLADAREANU S, BANACU M, NEACSU A, CALIN A. Predictive value of the AMH Level and serum estradiol for ovarian hyperstimulation syndrome in the assisted human reproduction. Rev.Chim.(Bucharest), 68, no 5, 2017, p.1118-1121

30. IONESCU C, MATEI A, NAVOLAN D, DIMITRIU M, BOHILTEA R, NEACSU A, ILINCA C, PLES L. Correlation of ultrasound features and the risk of ovarian malignancy algorithm score for different histopathological subtypes of benign adnexal masses. Medicine vol 97 issue 31 August 2018 e11762

31. CIRKEL U, SCHWEPPE KW, OCHS H, ET AL. Effects of LHRH agonist therapy in the treatment of endometriosis. In: Gonadotropin Down-regulation in Gynecological Practice, Chadha DR, Willemsen WNP (Eds), Aln R Liss, New York 1986. Vol 25, p.189

32. LIANG B, WU L, XU H, CHEUNG CW, FUNG WY, WONG SW, WANG CC. Efficacy, safety and recurrence of new progestins and selective progesterone-receptor modulator for the treatment of endometriosis: a comparison study in mice. Reprod Biol Endocrinol. 2018 Apr 3;16(1):32

33. DONNEZ J, HUDECEK R, DONNEZ O, MATULE D, ARHENDT H-J, ZATIK J, KASILOVSKIE Z, DUMITRASCU MC, FERNANDEZ H, BARLOW DH, ET AL. Efficacy and safety of repeated use of ulipristal acetate in uterine fibroids. Fertil Steril. 2015;103:519-27. e513

34. MICKS EA, JENSEN JT. Treatment of heavy menstrual bleeding with the estradiol valerate and dienogest oral contraceptive pill. Adv Ther. 2013;30:1-13

Manuscript received 22.09.2018